Video

Peyronie’s Disease: Surgical Approaches

Peyronie’s Disease: Surgical Approaches

Posted by | Aug 2024

William O. Brant, MD, FACS, FECSM, Urologist at the Veterans Affairs Medical Center in Salt Lake City, Utah, presents an analysis of surgical approaches for Peyronie’s disease. With a focus on both shortening and lengthening procedures, Dr. Brant delves into the intricacies of various surgical techniques, providing a thorough examination of each method’s benefits and considerations. In his meticulous exploration, Dr. Brant begins by discussing the placation technique, a procedure aimed at addressing the excessive curvature caused by Peyronie’s disease. He elucidates the surgical process, highlighting its potential for restoring penile function and improving patient satisfaction. Furthermore, Dr. Brant explores the outcomes of placation, including changes in penile length and erectile function, enabling readers to grasp the potential benefits and limitations associated with this approach. Moving forward, the discussion expands to encompass plaque incision and excision techniques, which involve the precise removal of the fibrous plaque responsible for the curvature. Beyond the technical aspects, Dr. Brant also emphasizes the importance of personalized decision-making in the management of Peyronie’s disease. He discusses the significance of considering individual patient needs, taking into account factors such as disease severity, patient preferences, and overall health. The presentation encompasses an array of clinical scenarios and surgical techniques, showcasing Dr. Brant’s wealth of experience and expertise in the field. From the assessment of deformities to the exploration of different incision options, the presentation offers a comprehensive overview of the surgical approaches available for Peyronie’s disease.

Read More
Therapy for High Risk NMIBC

Therapy for High Risk NMIBC

Posted by | Aug 2024

Colin P.N. Dinney, MD, defines the criteria that categorize patients as high-risk, such as tumor grade, size, and recurrence history. He underscores the importance of early and accurate diagnosis using advanced imaging techniques and molecular markers, which play a crucial role in guiding treatment decisions.

He focuses on Bacillus Calmette-Guérin (BCG) therapy, the gold standard for high-risk NMIBC. Dr. Dinney reviews BCG’s mechanisms of action, administration protocols, and factors influencing its efficacy. He also addresses the challenges posed by BCG shortages and the emergence of BCG-unresponsive disease, highlighting the need for alternative therapeutic strategies.

Further, Dr. Dinney discusses the potential of immune checkpoint inhibitors, targeted therapies, and gene therapy in the context of high-risk NMIBC. He presents data from recent clinical trials that demonstrate the promising results of these innovative approaches in achieving durable responses and reducing recurrence rates.

Read More
Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET Imaging

Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET Imaging

Posted by | Aug 2024

Andrew W. Hahn, MD, explores the treatment of oligometastatic prostate cancer in the context of advancements in PSMA PET imaging. Dr. Hahn examines the integration of systemic therapies with local treatments, discussing the benefits and challenges of combining androgen deprivation therapy (ADT) with newer agents like androgen receptor inhibitors and chemotherapy. The presentation also delves into the evolving role of PSMA-targeted radioligand therapy, outlining promising results from early-phase studies and ongoing research on this treatment modality.
A significant portion of the presentation is dedicated to the practical considerations and challenges associated with implementing PSMA PET imaging and MDT in clinical practice. Dr. Hahn addresses issues related to accessibility, cost, and the need for multidisciplinary collaboration to ensure the best patient outcomes.

Read More
Clinical Trials in Focal Therapy – Endpoint, Design, Updates

Clinical Trials in Focal Therapy – Endpoint, Design, Updates

Posted by | Aug 2024

Taimur Shah, MD, provides an in-depth analysis of clinical trials in focal therapy for prostate cancer, focusing on endpoints, design, and recent updates.

Dr. Shah emphasizes the importance of carefully defined endpoints in clinical trials for focal therapy, including oncologic control measures such as progression-free survival, biochemical recurrence rates, and cancer-specific mortality. Secondary endpoints typically assess functional outcomes, including urinary continence and sexual function, to gauge the impact on patients’ quality of life. These criteria are crucial for determining the effectiveness and safety of focal therapy compared to traditional treatments.

The design of clinical trials in focal therapy is discussed in detail. Dr. Shah highlights the need for robust methodologies, including randomized controlled trials (RCTs) and prospective cohort studies. He discusses the latest data on various focal therapy modalities, including high-intensity focused ultrasound (HIFU), cryoablation, and photodynamic therapy.

The presentation also addresses the challenges and limitations of current clinical trials. These include the need for standardized treatment protocols, variability in imaging and biopsy techniques, and the difficulty of conducting long-term follow-ups. Dr. Shah emphasizes the importance of continued research and collaboration among institutions to overcome these challenges and refine focal therapy approaches.

Read More